Galectin Therapeutics (GALT) Total Non-Current Liabilities (2010 - 2026)
Galectin Therapeutics' quarterly Total Non-Current Liabilities came in at $143.0 million in Q1 2026, up 17.56% year-on-year from $121.7 million in Q1 2025, and up 0.88% quarter-over-quarter from $141.8 million in Q4 2025.
Galectin Therapeutics has reported Total Non-Current Liabilities for 17 years, with the latest figure at $143.0 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities rose 17.56% year-over-year to $143.0 million; the trailing twelve-month figure through Mar 2026 stood at $143.0 million (up 17.56% YoY), and the FY2025 full-year result was $141.8 million, up 17.63% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $143.0 million, up from $141.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $143.0 million in Q1 2026, with the low at $39.6 million in Q1 2022.
- Average Total Non-Current Liabilities over 5 years is $93.5 million, with a median of $96.7 million recorded in 2024.
- Year-over-year, Total Non-Current Liabilities jumped 749.67% in 2022 and advanced 13.24% in 2025.
- Tracing GALT's Total Non-Current Liabilities over 5 years: stood at $53.3 million in 2022, then surged by 65.28% to $88.0 million in 2023, then jumped by 36.89% to $120.5 million in 2024, then gained by 17.63% to $141.8 million in 2025, then increased by 0.88% to $143.0 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $143.0 million (Q1 2026), $141.8 million (Q4 2025), and $136.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - | 143.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 143.02 Mn |
| Dec 31, 2025 | 141.77 Mn |
| Sep 30, 2025 | 136.45 Mn |
| Jun 30, 2025 | 131.23 Mn |
| Mar 31, 2025 | 121.65 Mn |
| Dec 31, 2024 | 120.52 Mn |
| Sep 30, 2024 | 120.25 Mn |
| Jun 30, 2024 | 109.14 Mn |
| Mar 31, 2024 | 96.29 Mn |
| Dec 31, 2023 | 88.01 Mn |
| Sep 30, 2023 | 72.44 Mn |
| Jun 30, 2023 | 71.05 Mn |
| Mar 31, 2023 | 62.39 Mn |
| Dec 31, 2022 | 53.37 Mn |
| Sep 30, 2022 | 39.95 Mn |
| Jun 30, 2022 | 40.98 Mn |
| Mar 31, 2022 | 39.53 Mn |
| Dec 31, 2021 | 38.72 Mn |
| Sep 30, 2021 | 28.79 Mn |
| Jun 30, 2021 | 16.29 Mn |
| Mar 31, 2021 | 4.66 Mn |
| Dec 31, 2020 | 5.41 Mn |
| Sep 30, 2020 | 2.49 Mn |
| Jun 30, 2020 | 4.28 Mn |
| Mar 31, 2020 | 1.32 Mn |
| Dec 31, 2019 | 2.82 Mn |
| Sep 30, 2019 | 1.22 Mn |
| Jun 30, 2019 | 1.32 Mn |
| Mar 31, 2019 | 907,000.00 |
| Dec 31, 2018 | 2.11 Mn |
| Dec 31, 2017 | 2.97 Mn |
| Dec 31, 2016 | 3.78 Mn |
| Dec 31, 2015 | 1.36 Mn |
| Mar 31, 2015 | 1.29 Mn |
| Dec 31, 2014 | 1.70 Mn |
| Sep 30, 2013 | 1.60 Mn |
| Jun 30, 2013 | 1.49 Mn |
| Mar 31, 2013 | 1.47 Mn |
| Dec 31, 2012 | 1.64 Mn |
| Jun 30, 2011 | 786,000.00 |
| Dec 31, 2010 | 1.77 Mn |